Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4663143> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q4663143 subject Q6814466.
- Q4663143 subject Q8460853.
- Q4663143 abstract "Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom. It is a fixed dose combination of a certain crystal form of lamivudine (3TC, Epivir) and the hemisulphate salt of abacavir (ABC, Ziagen). Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.".
- Q4663143 atcPrefix "J05".
- Q4663143 atcSuffix "AR02".
- Q4663143 casNumber "852337-16-7".
- Q4663143 pubchem "5273759".
- Q4663143 thumbnail Abacavir_and_lamivudine.svg?width=300.
- Q4663143 wikiPageWikiLink Q1046522.
- Q4663143 wikiPageWikiLink Q12199.
- Q4663143 wikiPageWikiLink Q12988589.
- Q4663143 wikiPageWikiLink Q1779868.
- Q4663143 wikiPageWikiLink Q18208897.
- Q4663143 wikiPageWikiLink Q304330.
- Q4663143 wikiPageWikiLink Q421559.
- Q4663143 wikiPageWikiLink Q422631.
- Q4663143 wikiPageWikiLink Q5456317.
- Q4663143 wikiPageWikiLink Q6814466.
- Q4663143 wikiPageWikiLink Q7929051.
- Q4663143 wikiPageWikiLink Q824258.
- Q4663143 wikiPageWikiLink Q8460853.
- Q4663143 wikiPageWikiLink Q898750.
- Q4663143 atcPrefix "J05".
- Q4663143 atcSuffix "AR02".
- Q4663143 casNumber "852337".
- Q4663143 pubchem "5273759".
- Q4663143 type ChemicalSubstance.
- Q4663143 type Drug.
- Q4663143 type ChemicalObject.
- Q4663143 type Thing.
- Q4663143 type Q8386.
- Q4663143 comment "Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom. It is a fixed dose combination of a certain crystal form of lamivudine (3TC, Epivir) and the hemisulphate salt of abacavir (ABC, Ziagen). Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.".
- Q4663143 label "Abacavir/lamivudine".
- Q4663143 depiction Abacavir_and_lamivudine.svg.